LYEL vs SILC Comparison

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.